UCB and Novartis to expand cooperation in Germany
UCB further strengthens its second largest market, Germany
24-Aug-2009 -
UCB and Novartis announced that they entered into a licensing agreement for cardiovascular and diabetes products in Germany. Under the agreement, UCB has extended commercial rights for the German market to the cardiovascular medication Provas® (valsartan) beyond 2011 and has licensed in ...
Germany
hypertension
internal medicine
+1